Inhibition of thrombin activity by a covalent-binding aptamer and reversal by the complementary strand antidote

2021 ◽  
Author(s):  
Yudai Tabuchi ◽  
Jay Yang ◽  
Masumi Taki

We created a DNA-aptamer-type covalent drug where the pharmacological effect can be reversed by the complementary strand antidote.

2009 ◽  
Vol 148 (1) ◽  
pp. 33-36 ◽  
Author(s):  
A. B. Dobrovolsky ◽  
E. V. Titaeva ◽  
S. G. Khaspekova ◽  
V. A. Spiridonova ◽  
A. M. Kopylov ◽  
...  

2021 ◽  
Vol 22 (16) ◽  
pp. 8664
Author(s):  
Agnieszka Kij ◽  
Anna Bar ◽  
Kamil Przyborowski ◽  
Bartosz Proniewski ◽  
Lukasz Mateuszuk ◽  
...  

Angiotensin II (Ang II) induces hypertension and endothelial dysfunction, but the involvement of thrombin in these responses is not clear. Here, we assessed the effects of the inhibition of thrombin activity by dabigatran on Ang II-induced hypertension and endothelial dysfunction in mice with a particular focus on NO- and 20-HETE-dependent pathways. As expected, dabigatran administration significantly delayed thrombin generation (CAT assay) in Ang II-treated hypertensive mice, and interestingly, it prevented endothelial dysfunction development, but it did not affect elevated blood pressure nor excessive aortic wall thickening. Dabigatran’s effects on endothelial function in Ang II-treated mice were evidenced by improved NO-dependent relaxation in the aorta in response to acetylcholine in vivo (MRI measurements) and increased systemic NO bioavailability (NO2− quantification) with a concomitant increased ex vivo production of endothelium-derived NO (EPR analysis). Dabigatran treatment also contributed to the reduction in the endothelial expression of pro-inflammatory vWF and ICAM-1. Interestingly, the fall in systemic NO bioavailability in Ang II-treated mice was associated with increased 20-HETE concentration in plasma (UPLC-MS/MS analysis), which was normalised by dabigatran treatment. Taking together, the inhibition of thrombin activity in Ang II-induced hypertension in mice improves the NO-dependent function of vascular endothelium and normalises the 20-HETE-depedent pathway without affecting the blood pressure and vascular remodelling.


1987 ◽  
Author(s):  
Maciej Dryjski ◽  
Be-Sheng Kuo ◽  
Thorir D Bjornsson

The inhibition of thrombin as well as of factor Xa has been thought to occur primarily in plasma through the neutralizing action of the serine protease inhibitor antithrombin III (AT-III). However, inhibition of thrombin and Xa by this mechanism may not be sufficient for effective elimination of these clotting factors in states of increased coagulation activity. The potential role of the vascular endothelium in the inhibition of clotting factor activities has therefore received attention in recent years. The aim of the present investigation was to characterize the binding and inhibition of thrombin and factor Xa to the vascular endothelial cell (EC), smooth muscle cell (SMC) and rat hepatoma cell (RHC) in vitro, as well as to evaluate the effects of plasma constituents upon the inhibition of these factors. Purified bovine thrombin and factor Xa were used. The enzymatic activities of both factors were assayed using chromogenic substrates. The cells were exposed for 5 U/ml thrombin or 0.5 U/ml factor Xa. After 10 minutes incubation, the initial thrombin activity in the solution had decreased by about 20% in case of EC and SMC and about 11% when incubated with RHC. Thrombin activity recovered from the cell surface amounted to 0.02 U/cm2. When the cells with the surface bound enzyme were incubated with defibrinogenated plasma or AT-III for 30 seconds, only about 10% and 25-40%, respectively, of initial activity could be found. In similar experiments with factor Xa, after 10 minutes incubation, the initial activity in the solution had decreased by 10%. Factor Xa activity recovered from the cell surface was 0.001 U/cm2. After 30 seconds exposure to AT-III, no cell surface related factor Xa activity was recovered, whereas 10% of the cell surface activity was recovered after incubation with defibrinogenated plasma. It is concluded that thrombin and factor Xa are taken up and inhibited by EC, SMC and RHC cell surfaces in similar ratios suggesting that cell surface-mediated inactivation of activated clotting factors is not restricted to vascular wall cells. The inactivation of factor Xa was dependent on AT-III, however, the inactivation of thrombin was further promoted by an additional unidentified plasma constituent


2016 ◽  
Vol 26 (5) ◽  
pp. 299-308 ◽  
Author(s):  
Elena Zavyalova ◽  
Grigory Tagiltsev ◽  
Roman Reshetnikov ◽  
Alexander Arutyunyan ◽  
Alexey Kopylov

2019 ◽  
Vol 7 ◽  
Author(s):  
Ting-Xuan Lin ◽  
Pei-Xin Lai ◽  
Ju-Yi Mao ◽  
Han-Wei Chu ◽  
Binesh Unnikrishnan ◽  
...  

1974 ◽  
Vol 31 (03) ◽  
pp. 439-451
Author(s):  
Robert H. Yue ◽  
Toby Starr ◽  
Menard M. Gertler

SummaryA simple quantitative method for the determination of antithrombin III in plasma is described. It is based on the preferential precipitation of plasma antithrombin activities by a chemical compound 2,5-diamino-7-ethoxyacridin lactate (rivanol). When the incubation time of plasma with rivanol took place within 0.5 and 2 hours under specifically controlled experimental conditions, rivanol precipitated α2-macro-globulin selectively and quantitatively without any effect on antithrombin III. In the presence of rivanol, the inhibition of thrombin by plasma antithrombin III followed a second-order reaction with a rate constant of 80 1/M/sec. In this assay procedure, only the initial thrombin activity and the 30 minutes residual thrombin activity are required to evaluate the amount of antithrombin III present in the plasma quantitatively. “With proper routine laboratory care, this assay system was found to be accurate and reproducible.


RSC Advances ◽  
2017 ◽  
Vol 7 (3) ◽  
pp. 1643-1645 ◽  
Author(s):  
Jieun Kim ◽  
Dajeong Kim ◽  
Jong Bum Lee

Here, we synthesized DNA microparticles comprised of thrombin binding aptamers via rolling circle amplification (RCA). These DNA aptamer particles could successfully load a number of thrombins and the complexes have shown improved thrombin activity.


Sign in / Sign up

Export Citation Format

Share Document